Abstract
Patients with non-small cell lung cancer (NSCLC) harboring anaplastic lymphoma kinase (ALK) gene rearrangements are treated with crizotinib. However, ......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
